8-K current report · filed Aug 5, 2026

Akebia Therapeutics, Inc. (AKBA) 8-K Current Report: August 5, 2026

Item 2.02Item EX-99.1AKBA overview

Short answer

Akebia Therapeutics, Inc. (AKBA) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results for quarter ended June 30, 2026, announced August 5, 2026.

Akebia Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 results for quarter ended June 30, 2026, announced August 5, 2026
  • Recent business highlights included in Exhibit 99.1, the company’s press release
  • Investor focus: quarterly financial performance and operating developments disclosed in the attached release

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $49.1M, down from $62.5M, as Auryxia fell to $25.5M amid generic competition
  • Vafseo revenue $21.3M, up 34% sequentially, with active patients exceeding 10,500 and prescribers reaching approximately 1,200
  • Net loss $8.9M versus $0.2M income, including $1.9M restructuring expense and higher commercialization and pipeline costs
  • Cash $155.5M at June 30, down from $184.8M at December 31, with refinancing of senior secured debt planned
  • VOICE interim analysis showed improved safety versus ESA, while ebribafusp Phase 2 enrollment targets up to 30 patients with initial data expected in 2027

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Akebia Therapeutics, Inc. 8-K filings

Get the next AKBA 8-K as it lands

Follow AKBA for push alerts, or ask the research agent what this filing means.